Earnings ·
Nanobiotix reports net loss of €34.3 million on revenue decline to €5.6 million
NBTXNanobiotix S.A.
Nanobiotix S.A. reported a net loss of €34.3 million for the six months ended June 30, 2026, compared to a net loss of €5.4 million in the prior year period. Revenue declined significantly to €5.6 million from €26.6 million, primarily due to the absence of a €21.2 million one-off positive revenue adjustment recognized in H1 2025 related to a contract modification with Janssen Pharmaceutica NV. Operating expenses decreased by €2.4 million to €23.5 million, driven by lower clinical study costs following the transfer of sponsorship for the NANORAY-312 trial and reduced patient recruitment. The financial result worsened due to increased interest costs totaling €14.5 million, largely attributable to fixed-rate interest on a royalty financing agreement with HealthCare Royalty Partners. In May 2026, the company completed an oversubscribed follow-on equity offering raising €86.0 million in gross proceeds, including pre-funded warrants. The company operates as a late-stage clinical biotechnology firm developing physics-based nanotherapeutic platforms for oncology and neurological diseases.